Year |
Citation |
Score |
2022 |
McNamara MC, Hosios AM, Torrence ME, Zhao T, Fraser C, Wilkinson M, Kwiatkowski DJ, Henske EP, Wu CL, Sarosiek KA, Valvezan AJ, Manning BD. Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. Iscience. 25: 105458. PMID 36388985 DOI: 10.1016/j.isci.2022.105458 |
0.316 |
|
2020 |
Gaglia G, Rashid R, Yapp C, Joshi GN, Li CG, Lindquist SL, Sarosiek KA, Whitesell L, Sorger PK, Santagata S. HSF1 phase transition mediates stress adaptation and cell fate decisions. Nature Cell Biology. PMID 32015439 DOI: 10.1038/S41556-019-0458-3 |
0.377 |
|
2019 |
Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, ... ... Sarosiek KA, et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Molecular Cancer Research : McR. PMID 31462500 DOI: 10.1158/1541-7786.Mcr-18-1243 |
0.431 |
|
2019 |
Lossos C, Liu Y, Kolb KE, Christie AL, van Scoyk A, Prakadan SM, Shigemori K, Stevenson KE, Morrow S, Plana OD, Fraser C, Jones KL, Liu H, Pallasch CP, Modiste R, ... ... Sarosiek KA, et al. Mechanisms of lymphoma clearance induced by high-dose alkylating agents. Cancer Discovery. PMID 31040105 DOI: 10.1158/2159-8290.Cd-18-1393 |
0.394 |
|
2019 |
Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nature Reviews. Molecular Cell Biology. PMID 30655609 DOI: 10.1038/S41580-018-0089-8 |
0.409 |
|
2019 |
Spetz J, Presser AG, Sarosiek KA. T Cells and Regulated Cell Death: Kill or Be Killed. International Review of Cell and Molecular Biology. 342: 27-71. PMID 30635093 DOI: 10.1016/Bs.Ircmb.2018.07.004 |
0.392 |
|
2019 |
Fraser C, Ryan J, Sarosiek K. BH3 Profiling: A Functional Assay to Measure Apoptotic Priming and Dependencies. Methods in Molecular Biology (Clifton, N.J.). 1877: 61-76. PMID 30535998 DOI: 10.1007/978-1-4939-8861-7_4 |
0.441 |
|
2018 |
Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, ... ... Sarosiek KA, et al. Exploiting MCL-1 dependency with combination MEK + MCL-1 inhibitors leads to induction of apoptosis and tumor regression in KRAS mutant non-small cell lung cancer. Cancer Discovery. PMID 30254092 DOI: 10.1158/2159-8290.Cd-18-0277 |
0.43 |
|
2018 |
McBrayer SK, Mayers JR, DiNatale GJ, Shi DD, Khanal J, Chakraborty AA, Sarosiek KA, Briggs KJ, Robbins AK, Sewastianik T, Shareef SJ, Olenchock BA, Parker SJ, Tateishi K, Spinelli JB, et al. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. PMID 30220459 DOI: 10.1016/J.Cell.2018.08.038 |
0.311 |
|
2018 |
Gutierrez-Martinez P, Hogdal L, Nagai M, Kruta M, Singh R, Sarosiek K, Nussenzweig A, Beerman I, Letai A, Rossi DJ. Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nature Cell Biology. PMID 29531308 DOI: 10.1038/S41556-018-0054-Y |
0.3 |
|
2018 |
Fraser C, Sanchorawala V, Sarosiek K, Sarosiek S. Clonal Plasma Cells in AL Amyloidosis Are Dependent on Anti-Apoptotic BCL-2 Family Proteins Blood. 132: 2654-2654. DOI: 10.1182/Blood-2018-99-120028 |
0.389 |
|
2018 |
Sarosiek K. p53: Jack of all (cell death) trades, master of all Science Translational Medicine. 10: eaar7526. DOI: 10.1126/Scitranslmed.Aar7526 |
0.365 |
|
2017 |
Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, et al. BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nature Communications. 8: 1123. PMID 29066722 DOI: 10.1038/S41467-017-01079-1 |
0.409 |
|
2017 |
Sarosiek K. Chemotherapy-treated cells go up in flames. Science Translational Medicine. 9. PMID 28515339 DOI: 10.1126/Scitranslmed.Aan4289 |
0.414 |
|
2017 |
Gunda V, Sarosiek KA, Brauner E, Kim YS, Amin S, Zhou Z, Letai A, Parangi S. Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis. Cancer Letters. PMID 28259821 DOI: 10.1016/J.Canlet.2017.02.028 |
0.438 |
|
2017 |
Sarosiek K. Searching for the ovarian cancer cell of origin Science Translational Medicine. 9: eaaq1227. DOI: 10.1126/Scitranslmed.Aaq1227 |
0.326 |
|
2017 |
Sarosiek K. Blocking cell death to enhance cell death Science Translational Medicine. 9: eaao6129. DOI: 10.1126/Scitranslmed.Aao6129 |
0.444 |
|
2016 |
Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, et al. Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. Cancer Cell. PMID 28017613 DOI: 10.1016/J.Ccell.2016.11.011 |
0.381 |
|
2016 |
Pécot J, Maillet L, Le Pen J, Vuillier C, Trécesson SC, Fétiveau A, Sarosiek KA, Bock FJ, Braun F, Letai A, Tait SW, Gautier F, Juin PP. Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. Cell Reports. 17: 3347-3358. PMID 28009301 DOI: 10.1016/J.Celrep.2016.11.064 |
0.407 |
|
2016 |
Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, ... Sarosiek KA, et al. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports. 17: 2367-2381. PMID 27880910 DOI: 10.1016/J.Celrep.2016.10.077 |
0.359 |
|
2016 |
Bhatt S, Sarosiek KA, Lossos IS. Interleukin 21 - its potential role in the therapy of B-cell lymphomas. Leukemia & Lymphoma. 1-13. PMID 27405876 DOI: 10.1080/10428194.2016.1201568 |
0.65 |
|
2016 |
Sarosiek KA, Letai A. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy with BH3 mimetics: recent successes, current challenges and future promise. The Febs Journal. PMID 26996748 DOI: 10.1111/Febs.13714 |
0.398 |
|
2016 |
Pen JL, Laurent M, Sarosiek K, Vuillier C, Gautier F, Montessuit S, Martinou J, Letaï A, Braun F, Juin P. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL Cell Death and Disease. 7: 0. PMID 26844698 DOI: 10.1038/Cddis.2015.400 |
0.401 |
|
2015 |
Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood. 126: 1555-64. PMID 26194763 DOI: 10.1182/Blood-2015-01-624585 |
0.728 |
|
2015 |
Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, Jänne PA, Amrein PC, Cichowski K, Drapkin R, Letai A. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 160: 977-89. PMID 25723171 DOI: 10.1016/J.Cell.2015.01.042 |
0.354 |
|
2015 |
Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma Blood. 126: 1555-1564. DOI: 10.1182/blood-2015-01-624585 |
0.663 |
|
2015 |
Sarosiek KA, Karst A, Winter P, Sorrentino A, Bandyopadhyay S, Goga A, Wood KC, Drapkin R, Letai A. Abstract 970: Broad therapy resistance is induced by suppression of apoptotic priming by lineage programs and oncogenic activation Cancer Research. 75: 970-970. DOI: 10.1158/1538-7445.Am2015-970 |
0.433 |
|
2015 |
Sarosiek KA, Ziller M, Fraser C, Bhola P, Ryan J, Deng J, Jian B, Goldenberg M, Madsen J, Carrasco R, Robinson S, Moslehi J, Letai A. Abstract 4728: Apoptotic priming is regulated by a developmental program and predisposes children to therapy-induced toxicity Cancer Research. 75: 4728-4728. DOI: 10.1158/1538-7445.Am2015-4728 |
0.359 |
|
2014 |
Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Science Signaling. 7: ra122. PMID 25538080 DOI: 10.1126/Scisignal.2005301 |
0.433 |
|
2014 |
Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Research. 74: 3146-56. PMID 24675361 DOI: 10.1158/0008-5472.Can-13-3728 |
0.437 |
|
2014 |
Bhatt S, Sarosiek K, Parvin S, Matthews JM, Zhao D, Lossos IS. Interleukin-21 Potently Induces Direct and Indirect Cytotoxicity of Mantle Cell Lymphoma Blood. 124: 1776-1776. DOI: 10.1182/Blood.V124.21.1776.1776 |
0.732 |
|
2013 |
Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proceedings of the National Academy of Sciences of the United States of America. 110: 17041-6. PMID 24085845 DOI: 10.1073/Pnas.1305170110 |
0.335 |
|
2013 |
Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, Flanagan A, Andrews DW, Sorger P, Letai A. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Molecular Cell. 51: 751-65. PMID 24074954 DOI: 10.1016/J.Molcel.2013.08.048 |
0.411 |
|
2013 |
Sarosiek KA, Ni Chonghaile T, Letai A. Mitochondria: gatekeepers of response to chemotherapy. Trends in Cell Biology. 23: 612-9. PMID 24060597 DOI: 10.1016/J.Tcb.2013.08.003 |
0.438 |
|
2013 |
Bhatt S, Sarosiek KA, Lossos IS. Abstract LB-328: Preclinical activity of interleukin 21 in mantle cell lymphoma. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-328 |
0.575 |
|
2013 |
Patel LG, Paranal RM, Ryan J, Sarosiek K, Bradner JE, Letai A. Abstract 4610: Small molecule inhibitors of membrane-bound MCL-1 and BCL-2. Cancer Research. 73: 4610-4610. DOI: 10.1158/1538-7445.Am2013-4610 |
0.335 |
|
2013 |
Johnson N, Johnson SF, Wang Y, Bernhardy A, Yao W, Choi Y, Capelletti M, Sarosiek K, Moreau L, Chowdhury D, Liu J, D'Andrea A, Miron A, Wickramanayake A, Harrell M, et al. Abstract C74: Stabilization of mutant BRCA1 confers PARP inhibitor and platinum resistance. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C74 |
0.349 |
|
2012 |
Qi L, Xu C, Sarosiek K, Ligon A, Rodig S, Wong K, Letai A, Shapiro GI. Abstract 2016: A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk)9 inhibitionin vitroandin vivo Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2012-2016 |
0.368 |
|
2011 |
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (New York, N.Y.). 334: 1129-33. PMID 22033517 DOI: 10.1126/Science.1206727 |
0.397 |
|
2011 |
Chonghaile TN, Sarosiek K, Ryan J, Moore VDG, Tai Y, Richardson PG, Anderson KC, Stone RM, DeAngelo DJ, Mitsiades CS, Sallan SE, Hirsch M, Silverman LB, Carrasco R, Letai AG. Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index Blood. 118: 1442-1442. DOI: 10.1182/Blood.V118.21.1442.1442 |
0.353 |
|
2011 |
Qi L, Xu C, Sarosiek KA, Ligon AH, Rodig SJ, Wong K, Letai AG, Shapiro GI. Abstract LB-22: A subset of small cell lung cancer (SCLC) cell lines is Mcl-1-dependent and responds to cyclin-dependent kinase (cdk)9 inhibition in vitro and in vivo Cancer Research. 72: 2016-2016. DOI: 10.1158/1538-7445.Am2011-Lb-22 |
0.488 |
|
2010 |
Jiang X, Lu X, McNamara G, Liu X, Cubedo E, Sarosiek KA, Sánchez-García I, Helfman DM, Lossos IS. HGAL, a germinal center specific protein, decreases lymphoma cell motility by modulation of the RhoA signaling pathway. Blood. 116: 5217-27. PMID 20844236 DOI: 10.1182/Blood-2010-04-281568 |
0.575 |
|
2010 |
Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 107: 13069-74. PMID 20615981 DOI: 10.1073/Pnas.1002985107 |
0.582 |
|
2010 |
Sarosiek KA, Malumbres R, Nechushtan H, Gentles AJ, Avisar E, Lossos IS. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood. 115: 570-80. PMID 19965678 DOI: 10.1182/Blood-2009-08-239996 |
0.675 |
|
2009 |
Sarosiek KA, Nechushtan H, Lu X, Rosenblatt JD, Lossos IS. Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy. British Journal of Haematology. 147: 308-18. PMID 19694722 DOI: 10.1111/J.1365-2141.2009.07851.X |
0.659 |
|
2009 |
Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD, Tibshirani R, Lossos IS. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 113: 3754-64. PMID 19047678 DOI: 10.1182/Blood-2008-10-184077 |
0.511 |
|
2009 |
Jiang X, Lu X, Mcnamara G, Liu X, Sarosiek KA, Helfman DM, Lossos IS. HGAL, a Lymphoma Prognostic Biomarker, Regulates Lymphocyte and Lymphoma Cell Motility by Modulation of RhoA Signaling Pathway. Blood. 114: 316-316. DOI: 10.1182/Blood.V114.22.316.316 |
0.602 |
|
2008 |
Lu X, Malumbres R, Shields B, Jiang X, Sarosiek KA, Natkunam Y, Tiganis T, Lossos IS. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood. 112: 4098-108. PMID 18716132 DOI: 10.1182/Blood-2008-03-148726 |
0.61 |
|
2008 |
Sarosiek KA, Nechushtan H, Avisar E, Lossos IS. Interleukin-21 Induces Cell Cycle Arrest and Apoptosis of Diffuse Large B-Cell Lymphomas (DLBCL) Via Activation of STAT3 and Upregulation of C-Myc Blood. 112: 601-601. DOI: 10.1182/Blood.V112.11.601.601 |
0.683 |
|
2007 |
Lu X, Chen J, Sasmono RT, Hsi ED, Sarosiek KA, Tiganis T, Lossos IS. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Molecular and Cellular Biology. 27: 2166-79. PMID 17210636 DOI: 10.1128/Mcb.01234-06 |
0.65 |
|
2006 |
Sarosiek KA, Chen J, Pham DG, Nechushtan H, Avisar E, Kindsvogel W, Lossos IS. Interleukin-21-Induced Apoptosis and Cell Death of Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines and Primary Tumors Are Associated with an Induction of Bim. Blood. 108: 2503-2503. DOI: 10.1182/Blood.V108.11.2503.2503 |
0.664 |
|
Show low-probability matches. |